BioMarin Pharmaceutical Inc. - Common Stock (BMRN) Stock Analysis — Latest Investor Quotes & Trade Calls

Biomarin surges on acquisition move to bolster rare disease pipeline

"Yes, this stock is up in a big way. It's up 17%, biggest jump since November 16. Biomarin Pharm Pharmaceutical BMRN. They agreed to buy Amicus Therapeutics, which is a biotech company that will help the company expand its treatments for rare diseases. So, they specialize in rare disease. And that stock, Amicus, is also up in a pretty big way with some double digit gain. Deal news in the pharma industry is clearly driving the move."

Biomarin (BMRN) experienced a sharp 17% jump following news of its acquisition of Amicus Therapeutics. The move is seen as a strategic play to expand its rare disease treatment portfolio, with the market responding positively to the deal news.

Biomarin's Deal Sparks 17% Jump

"Finally, a Biomarin company, Biomarin, ticker BMRN. It's up 17% - the biggest jump since November 2016 on deal news. They agreed to buy Amicus Therapeutics for about $4.8 billion. And this is a company that has treatments for rare diseases, so investors are taking this as now Biomarin is going to be able to expand its portfolio of treatments. It has pricing power for these rare diseases."

Biomarin shares surged 17% following the announcement of its $4.8 billion acquisition of Amicus Therapeutics, with investors expecting expanded treatment portfolios and strengthened pricing power in the rare disease market.